360 related articles for article (PubMed ID: 35353605)
1. α-Synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity.
Ghanem SS; Majbour NK; Vaikath NN; Ardah MT; Erskine D; Jensen NM; Fayyad M; Sudhakaran IP; Vasili E; Melachroinou K; Abdi IY; Poggiolini I; Santos P; Dorn A; Carloni P; Vekrellis K; Attems J; McKeith I; Outeiro TF; Jensen PH; El-Agnaf OMA
Proc Natl Acad Sci U S A; 2022 Apr; 119(15):e2109617119. PubMed ID: 35353605
[TBL] [Abstract][Full Text] [Related]
2. Polo-like kinase 2 inhibition reduces serine-129 phosphorylation of physiological nuclear alpha-synuclein but not of the aggregated alpha-synuclein.
Elfarrash S; Jensen NM; Ferreira N; Schmidt SI; Gregersen E; Vestergaard MV; Nabavi S; Meyer M; Jensen PH
PLoS One; 2021; 16(10):e0252635. PubMed ID: 34613964
[TBL] [Abstract][Full Text] [Related]
3. Fibrillar form of α-synuclein-specific scFv antibody inhibits α-synuclein seeds induced aggregation and toxicity.
Gupta V; Salim S; Hmila I; Vaikath NN; Sudhakaran IP; Ghanem SS; Majbour NK; Abdulla SA; Emara MM; Abdesselem HB; Lukacsovich T; Erskine D; El-Agnaf OMA
Sci Rep; 2020 May; 10(1):8137. PubMed ID: 32424162
[TBL] [Abstract][Full Text] [Related]
4. Generation of monoclonal antibodies against phosphorylated α-Synuclein at serine 129: Research tools for synucleinopathies.
Fayyad M; Majbour NK; Vaikath NN; Erskine D; El-Tarawneh H; Sudhakaran IP; Abdesselem H; El-Agnaf OMA
Neurosci Lett; 2020 Apr; 725():134899. PubMed ID: 32156613
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of α-Synuclein Seeding-Dependent Aggregation by ssDNA Aptamers Specific to C-Terminally Truncated α-Synuclein Fibrils.
Hmila I; Sudhakaran IP; Ghanem SS; Vaikath NN; Poggiolini I; Abdesselem H; El-Agnaf OMA
ACS Chem Neurosci; 2022 Dec; 13(23):3330-3341. PubMed ID: 36348612
[TBL] [Abstract][Full Text] [Related]
6. Investigating the presence of doubly phosphorylated α-synuclein at tyrosine 125 and serine 129 in idiopathic Lewy body diseases.
Fayyad M; Erskine D; Majbour NK; Vaikath NN; Ghanem SS; Sudhakaran IP; Abdesselem H; Lamprokostopoulou A; Vekrellis K; Morris CM; Attems J; El-Agnaf OMA
Brain Pathol; 2020 Jul; 30(4):831-843. PubMed ID: 32324926
[TBL] [Abstract][Full Text] [Related]
7. SMG1 identified as a regulator of Parkinson's disease-associated alpha-synuclein through siRNA screening.
Henderson-Smith A; Chow D; Meechoovet B; Aziz M; Jacobson SA; Shill HA; Sabbagh MN; Caviness JN; Adler CH; Driver-Dunckley ED; Beach TG; Yin H; Dunckley T
PLoS One; 2013; 8(10):e77711. PubMed ID: 24204929
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneity in α-synuclein subtypes and their expression in cortical brain tissue lysates from Lewy body diseases and Alzheimer's disease.
Vaikath NN; Erskine D; Morris CM; Majbour NK; Vekrellis K; Li JY; El-Agnaf OMA
Neuropathol Appl Neurobiol; 2019 Oct; 45(6):597-608. PubMed ID: 30422353
[TBL] [Abstract][Full Text] [Related]
9. Changes in properties of serine 129 phosphorylated α-synuclein with progression of Lewy-type histopathology in human brains.
Walker DG; Lue LF; Adler CH; Shill HA; Caviness JN; Sabbagh MN; Akiyama H; Serrano GE; Sue LI; Beach TG;
Exp Neurol; 2013 Feb; 240():190-204. PubMed ID: 23201181
[TBL] [Abstract][Full Text] [Related]
10. Implication of Alpha-Synuclein Phosphorylation at S129 in Synucleinopathies: What Have We Learned in the Last Decade?
Oueslati A
J Parkinsons Dis; 2016; 6(1):39-51. PubMed ID: 27003784
[TBL] [Abstract][Full Text] [Related]
11. α-Synuclein fibril-specific nanobody reduces prion-like α-synuclein spreading in mice.
Butler YR; Liu Y; Kumbhar R; Zhao P; Gadhave K; Wang N; Li Y; Mao X; Wang W
Nat Commun; 2022 Jul; 13(1):4060. PubMed ID: 35853942
[TBL] [Abstract][Full Text] [Related]
12. Effects of Serine 129 Phosphorylation on α-Synuclein Aggregation, Membrane Association, and Internalization.
Samuel F; Flavin WP; Iqbal S; Pacelli C; Sri Renganathan SD; Trudeau LE; Campbell EM; Fraser PE; Tandon A
J Biol Chem; 2016 Feb; 291(9):4374-85. PubMed ID: 26719332
[TBL] [Abstract][Full Text] [Related]
13. RT-QuIC Using C-Terminally Truncated α-Synuclein Forms Detects Differences in Seeding Propensity of Different Brain Regions from Synucleinopathies.
Poggiolini I; Erskine D; Vaikath NN; Ponraj J; Mansour S; Morris CM; El-Agnaf OMA
Biomolecules; 2021 May; 11(6):. PubMed ID: 34072869
[TBL] [Abstract][Full Text] [Related]
14. Association between CSF alpha-synuclein seeding activity and genetic status in Parkinson's disease and dementia with Lewy bodies.
Brockmann K; Quadalti C; Lerche S; Rossi M; Wurster I; Baiardi S; Roeben B; Mammana A; Zimmermann M; Hauser AK; Deuschle C; Schulte C; Waniek K; Lachmann I; Sjödin S; Brinkmalm A; Blennow K; Zetterberg H; Gasser T; Parchi P
Acta Neuropathol Commun; 2021 Oct; 9(1):175. PubMed ID: 34717775
[TBL] [Abstract][Full Text] [Related]
15. Lewy-like aggregation of α-synuclein reduces protein phosphatase 2A activity in vitro and in vivo.
Wu J; Lou H; Alerte TN; Stachowski EK; Chen J; Singleton AB; Hamilton RL; Perez RG
Neuroscience; 2012 Apr; 207():288-97. PubMed ID: 22326202
[TBL] [Abstract][Full Text] [Related]
16. Alteration of Structure and Aggregation of α-Synuclein by Familial Parkinson's Disease Associated Mutations.
Sahay S; Ghosh D; Singh PK; Maji SK
Curr Protein Pept Sci; 2017; 18(7):656-676. PubMed ID: 26972727
[TBL] [Abstract][Full Text] [Related]
17. C-terminal truncation exacerbates the aggregation and cytotoxicity of α-Synuclein: A vicious cycle in Parkinson's disease.
Ma L; Yang C; Zhang X; Li Y; Wang S; Zheng L; Huang K
Biochim Biophys Acta Mol Basis Dis; 2018 Dec; 1864(12):3714-3725. PubMed ID: 30290273
[TBL] [Abstract][Full Text] [Related]
18. Mechanistic basis for receptor-mediated pathological α-synuclein fibril cell-to-cell transmission in Parkinson's disease.
Zhang S; Liu YQ; Jia C; Lim YJ; Feng G; Xu E; Long H; Kimura Y; Tao Y; Zhao C; Wang C; Liu Z; Hu JJ; Ma MR; Liu Z; Jiang L; Li D; Wang R; Dawson VL; Dawson TM; Li YM; Mao X; Liu C
Proc Natl Acad Sci U S A; 2021 Jun; 118(26):. PubMed ID: 34172566
[TBL] [Abstract][Full Text] [Related]
19. Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions.
Paleologou KE; Oueslati A; Shakked G; Rospigliosi CC; Kim HY; Lamberto GR; Fernandez CO; Schmid A; Chegini F; Gai WP; Chiappe D; Moniatte M; Schneider BL; Aebischer P; Eliezer D; Zweckstetter M; Masliah E; Lashuel HA
J Neurosci; 2010 Mar; 30(9):3184-98. PubMed ID: 20203178
[TBL] [Abstract][Full Text] [Related]
20. Skin α-synuclein deposits differ in clinical variants of synucleinopathy: an in vivo study.
Donadio V; Incensi A; El-Agnaf O; Rizzo G; Vaikath N; Del Sorbo F; Scaglione C; Capellari S; Elia A; Stanzani Maserati M; Pantieri R; Liguori R
Sci Rep; 2018 Sep; 8(1):14246. PubMed ID: 30250046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
